But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discovering value stocks, but we have found that ...

Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...

Extending the gains in the previous six sessions, the Japanese market is significantly higher on Friday, following the broadly ...

Esperion Therapeutics, Inc.’s ESPR share price has surged by 5.18%, which has investors questioning if this is right time to ...

Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomasRelapsed/refractory (R/R ...

The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...

Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas ...

Cells have a mailing system of sorts. They can release tiny molecular balls, called extracellular vesicles (EVs), that ...

Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...